Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAvicanna Inc

Avicanna Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.105 CAD -0.01 ( 4.55%)
Last update at 2026-11-05T18:43:00Z
VOLUME
95000
Market Cap
18.87M

Momentum Score

…

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol flower for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.10
Low
0.11
High
52 Week Price Range
0.14
Low
0.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Avicanna Inc. is a Canada-listed biopharma and consumer health company developing and commercializing cannabinoid-based medical and wellness products. Long-term growth drivers include expanding regulatory acceptance of medical cannabis, a developing therapeutic and consumer product pipeline, and scaling manufacturing and international distribution. The company may appeal to investors seeking exposure to specialized cannabinoid therapeutics and vertically integrated product delivery.

Key risks include regulatory and clinical development uncertainty, strong competition in pharmaceutical and consumer cannabis markets, and financing and liquidity pressures that may limit execution.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.11
Dividend Yield
-
Revenue TTM
25.48M
Revenue Per Share
0.22
Gross Profit TTM
13.52M
Debt / Equity
-16.03
ROE
-26.17%
Net Debt
-0.28M
ROCE
-22.51%
Diluted EPS TTM
-0.02

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.76M -3.62M -8.74M -14.74M -16.76M
Net income -2.84M -3.62M -8.74M -17.22M -16.77M
Selling general administrative - 12.88M 11.89M 9.61M 12.53M
Selling and marketing expenses - 3.19M 2.16M 0.38M 0.35M
Gross profit 12.84M 12.90M 6.66M 1.12M 2.83M
Reconciled depreciation - 0.85M 0.78M 0.89M 0.89M
Ebit -2.72M -3.28M -8.13M -10.58M -10.83M
Ebitda -1.97M -2.43M -7.36M -9.69M -9.94M
Depreciation and amortization 0.74M 0.85M 0.78M 0.89M 0.89M
Operating income -2.72M -4.68M -7.93M -10.58M -10.83M
Other operating expenses 28.19M 30.14M 25.17M 14.46M 14.68M
Interest expense 0.05M 0.33M 0.61M 1.67M 0.74M
Tax provision - - - 0.00M 0.01M
Interest income - 0.14M 0.58M 1.51M 1.82M
Net interest income - -0.33M -0.61M -1.67M -0.74M
Income tax expense - - -0.86M 2.48M 0.01M
Total revenue 25.48M 25.46M 16.79M 4.05M 3.27M
Total operating expenses 15.56M 17.58M 15.04M 11.53M 14.25M
Cost of revenue 12.64M 12.56M 10.13M 2.93M 0.44M
Total other income expense net -0.04M 1.06M -0.81M -4.16M -5.93M
Net income from continuing ops - -3.62M -8.74M -14.74M -16.77M
Net income applicable to common shares - -3.62M -8.74M -14.74M -16.77M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 21.24M 20.12M 21.97M 17.62M 22.30M
Intangible assets 0.63M 0.87M 1.19M 0.17M 0.30M
Other current assets 0.22M - 0.47M 0.48M 0.90M
Total liab 9.86M 10.38M 14.00M 14.16M 15.39M
Total stockholder equity 2.84M 2.31M -0.11M -0.38M 1.15M
Other current liab 0.29M 0.30M 1.39M 3.84M 3.66M
Common stock 88.26M - 81.03M 74.89M 66.24M
Capital stock - 87.00M 81.03M 74.89M 66.24M
Retained earnings -105.24M -102.09M -98.71M -90.83M -77.41M
Other liab - - - 2.35M 2.78M
Good will 0.33M 0.33M 0.33M - -
Other assets - - - - 0.00M
Cash 0.28M 0.45M 0.48M 1.19M 0.03M
Total current liabilities 9.18M 9.27M 11.97M 11.41M 12.20M
Current deferred revenue 0.38M - - - -
Net debt -0.28M - 1.33M 2.02M 1.63M
Short term debt - - 1.71M 2.81M 1.25M
Short long term debt - - 1.56M 2.66M 1.09M
Short long term debt total - - 1.80M 3.21M 1.66M
Other stockholder equity - - - 18.52M 16.47M
Property plant equipment - - - 10.39M 14.47M
Total current assets 7.90M 7.64M 8.46M 7.06M 7.35M
Long term investments - - - 0.00M 0.18M
Net tangible assets - - - - 0.85M
Short term investments - - - - 0.00M
Net receivables 3.55M 2.95M 2.97M 2.15M 2.34M
Long term debt - - - 0.18M 0.42M
Inventory 3.85M 3.97M 4.54M 3.24M 4.09M
Accounts payable 8.51M 7.77M 8.87M 4.75M 7.29M
Accumulated other comprehensive income 19.82M - 17.58M -2.97M -4.16M
Non current assets total 13.35M 12.48M 13.51M 10.55M 14.95M
Capital lease obligations - 0.11M 0.25M 0.37M 0.16M
Long term debt total - - - 0.40M 0.42M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.40M -3.05M 0.81M 1.25M
Change to liabilities - - - 0.00M 0.81M
Total cashflows from investing activities -0.26M -0.40M -3.05M 0.81M 0.76M
Net borrowings - -1.83M -0.55M - 0.88M
Total cash from financing activities 0.96M 3.41M 3.55M 9.90M 10.06M
Change to operating activities - - - - -0.01M
Net income -2.84M -3.62M -8.74M -14.74M -16.77M
Change in cash -0.17M -0.03M -0.72M 1.16M -1.24M
Begin period cash flow 0.45M 0.48M 1.19M 0.03M 1.27M
End period cash flow 0.28M 0.45M 0.48M 1.19M 0.03M
Total cash from operating activities -1.18M -2.55M -1.40M -7.44M -11.66M
Issuance of capital stock - 4.80M 2.08M 9.08M 9.09M
Depreciation 0.74M 0.85M 0.78M 0.89M 0.89M
Other cashflows from investing activities - 0.00M -0.49M 0.88M 1.55M
Change to inventory -0.36M 0.57M 1.16M 0.87M -2.16M
Change to account receivables -0.98M -0.26M -1.25M 0.37M -1.50M
Sale purchase of stock - 4.93M 3.34M 9.08M 9.18M
Other cashflows from financing activities -0.04M 0.44M 2.02M 2.23M 2.38M
Change to netincome - - - - 6.67M
Capital expenditures 0.26M 0.40M 0.56M 0.07M 0.79M
Change in working capital -0.06M -0.79M 4.36M 1.43M -2.45M
Stock based compensation - 1.57M 1.94M 1.04M 1.31M
Other non cash items 0.98M -0.57M 0.26M 3.94M 5.32M
Free cash flow -1.44M -2.95M -1.96M -7.50M -12.45M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AVCN
Avicanna Inc		 -0.01
4.55%		 0.10 - - 0.74 6.41 0.71 -4.26
CURA
Curaleaf Holdings Inc.		 -0.01
0.07%		 13.39 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 -0.44
3.77%		 11.23 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 0.33
6.69%		 5.26 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 -0.23
5.54%		 3.92 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

Avicanna Inc

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol flower for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

480 University Avenue, Toronto, ON, Canada, M5G 1V2

647 243 5283

https://www.avicanna.com

112

Name Title Year Born
Mr. Aras Azadian B.Econ, Mba Co-Founder, CEO & Director NA
Dr. Frantz Le Devedec Exec. VP of R&D NA
Mr. Roland Alvarez SVP of Technical Operations NA
Ms. Ivana Maric Exec. VP of Marketing NA
Dr. Carlos Enrique Maldonado Muete SVP of Clinical Devel. NA
Ms. Caitlin Johnston Sr. VP of Strategic Partnerships & Patient Access NA
Mr. Phillip Cardella C.A., CPA Chief Financial Officer NA
Ms. Ivana Maric Executive Vice President of Marketing NA
Mr. Stephen Kim Chief Legal Officer & General Counsel of Avicanna USA Inc. NA
Dr. Karolina Urban Executive Vice President of Scientific & Medical Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DHT-U
CAD 13.53
+16.44%
LIF
CAD 22.04
+8.62%
TOI
CAD 103.80
+7.09%
CRON
CAD 5.26
+6.69%
CIA
CAD 2.04
+6.25%
ITH
CAD 1.61
-34.02%
IFOS
CAD 1.65
-22.90%
TNZ
CAD 49.70
-19.58%
KEEL
CAD 2.36
-19.45%
GIL
CAD 49.36
-18.33%

Equity Sectors*

  • Basic Materials

    -2.18%

  • Communication Services

    +0.95%

  • Consumer Cyclical

    -2.25%

  • Consumer Defensive

    -0.68%

  • Energy

    -2.93%

  • Financial Services

    -2.26%

  • Healthcare

    -0.46%

  • Industrials

    -3.70%

  • Real Estate

    -0.06%

  • Technology

    -3.32%

  • Utilities

    -0.50%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…